accur
time
diagnosi
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
critic
step
prevent
anoth
global
outbreak
studi
serum
specimen
collect
patient
initi
report
infect
sarscov
sera
test
n
protein
sarscov
use
antigen
captur
enzymelink
immunosorb
assay
elisa
base
monoclon
antibodi
n
protein
sarscov
compar
control
serum
sampl
healthi
donor
nonsar
febril
patient
result
n
protein
detect
analysi
directli
relat
serolog
analysi
data
sar
patient
test
posit
neutral
test
sera
collect
day
onset
symptom
posit
n
protein
n
protein
detect
beyond
day
group
posit
rate
n
protein
sera
collect
day
onset
symptom
sampl
serolog
confirm
patient
respect
sera
serolog
testneg
patient
rate
respect
n
protein
detect
patient
case
initi
suspect
sar
serolog
proven
neg
sar
serum
sampl
healthi
donor
nonsar
febril
patient
specif
assay
furthermor
sera
collect
four
patient
sar
recurr
guangzhou
sera
collect
day
onset
symptom
posit
n
protein
n
protein
detect
exhibit
high
posit
rate
day
day
onset
symptom
neutral
testposit
sar
patient
serolog
confirm
patient
n
protein
detect
rate
continu
decreas
begin
day
n
protein
detect
beyond
day
onset
symptom
conclus
antigen
captur
elisa
reveal
high
n
protein
detect
rate
acutephas
sera
patient
sar
make
use
earli
diagnosi
sar
sever
acut
respiratori
syndrom
sar
emerg
infecti
diseas
signific
public
health
concern
due
recurr
sar
guangzhou
beij
china
would
like
stress
tremend
import
sensit
easi
reliabl
earli
diagnosi
sar
coronaviru
sarscov
infect
three
major
diagnost
method
current
avail
viral
rna
detect
use
realtim
revers
transcript
rt
pcr
ii
antibodi
detect
use
indirect
immunofluoresc
assay
iii
use
recombin
n
protein
cultur
extract
sarscovbas
enzymelink
immunosorb
assay
elisa
although
rtpcr
use
assay
earli
phase
sarscov
infect
regard
sensit
reli
heavili
experienc
technician
special
laboratori
equip
sometim
provid
falseposit
result
due
contamin
serolog
test
howev
provid
earli
diagnosi
sinc
median
time
seroconvers
patient
sar
day
onset
symptom
sinc
sarscov
appear
blood
much
earlier
antibodi
identif
sarscov
antigen
sera
may
provid
possibl
method
earli
diagnosi
sar
sinc
nucleocapsid
n
protein
known
coronavirus
rel
conserv
immunogen
abundantli
express
infect
tri
determin
whether
n
protein
potenti
earli
diagnost
marker
sar
recent
report
develop
antigencaptur
elisa
base
monoclon
antibodi
mab
n
protein
sarscov
high
level
circul
n
protein
detect
sera
patient
sar
studi
evalu
earli
diagnost
valu
use
larg
number
clinic
sampl
collect
februari
may
sar
epidem
guangzhou
peopl
republ
china
serum
specimen
recurr
sar
guangzhou
also
analyz
total
serum
specimen
collect
day
onset
symptom
patient
report
probabl
suspici
symptom
sar
februari
may
sar
epidem
guangzhou
patient
pair
serum
specimen
avail
serolog
analysi
acutephas
serum
specimen
collect
day
day
convalescentphas
serum
specimen
subsequ
obtain
day
longer
onset
ill
sixteen
serum
specimen
collect
four
patient
recurr
sar
guangzhou
decemb
januari
anoth
serum
specimen
use
control
sampl
sera
identifi
posit
influenza
immunoglobulin
g
igg
antibodi
fourfold
increas
antibodi
titer
sera
identifi
posit
dengu
igm
antibodi
sera
identifi
posit
measl
igm
antibodi
sera
healthi
blood
donor
serum
specimen
store
test
mabbas
antigen
captur
elisa
detect
sarscov
nucleocapsid
protein
clone
purif
glutathion
stransferasenucleocapsid
fusion
protein
develop
monoclon
antibodi
specif
n
protein
sarscov
report
previous
evalu
mabbas
elisa
detect
n
protein
sarscov
sera
viral
cell
cultur
supernat
describ
previous
briefli
costar
microtit
well
corn
incorpor
coat
mixtur
three
differ
antinucleocapsid
monoclon
antibodi
vacuum
dri
store
use
one
hundr
microlit
serum
ad
well
microtit
plate
coat
mixtur
three
antinucleocapsid
protein
mab
plate
incub
min
well
wash
phosphatebuff
salin
tween
antinucleocapsid
rabbit
serum
ad
dilut
plate
content
incub
h
well
wash
dilut
horseradish
peroxidaseconjug
goat
antirabbit
antibodi
zyme
laboratori
inc
south
san
francisco
calif
ad
three
wash
l
tetramethylbenzidin
solut
ad
well
reaction
stop
ad
l
n
sulfur
acid
plate
examin
nm
sampl
absorb
nm
cutoff
valu
mean
neg
control
standard
deviat
healthi
blood
donor
consid
posit
detect
sarscov
neutral
activ
neutral
test
serum
specimen
test
neutral
activ
accord
previous
describ
procedur
modif
briefli
heat
serum
specimen
serial
dilut
mix
tissu
cultur
infect
dose
sarscov
incub
h
mixtur
inocul
triplic
plate
vero
cell
cultur
cultur
held
co
daili
observ
cytopath
effect
cpe
result
determin
incub
sampl
consid
posit
neutral
antibodi
exhibit
least
fourfold
increas
titer
acuteand
convalescentphas
serum
specimen
pair
specimen
group
detect
sarscovspecif
igg
antibodi
indirect
elisa
igg
antibodi
sarscov
test
use
elisa
test
kit
manufactur
beij
huada
gbi
biotechnolog
co
ltd
beij
peopl
republ
china
assay
perform
accord
manufactur
instruct
one
hundr
microlit
specimen
diluent
ad
well
l
sera
ad
mix
incub
min
plate
wash
six
time
wash
solut
l
work
conjug
antihuman
igg
horseradish
peroxidas
conjug
ad
incub
min
plate
wash
l
substrat
ad
incub
min
reaction
stop
ad
l
stop
solut
plate
examin
nm
sampl
absorb
nm
cutoff
valu
mean
neg
control
consid
posit
ensur
biosafeti
experi
use
sera
patient
elisa
perform
biosafeti
level
laboratori
neutral
test
perform
biosafeti
level
laboratori
serum
specimen
specimen
test
n
protein
sarscov
use
mabbas
antigen
captur
elisa
patient
report
like
infect
sarscov
patient
divid
four
group
use
confirm
serolog
diagnosi
result
n
protein
detect
obtain
directli
relat
serolog
analysi
data
group
compris
patient
pair
two
serum
specimen
subsequ
confirm
sarscov
infect
basi
neutral
test
posit
seroconvers
patient
serum
specimen
taken
day
day
onset
ill
avail
n
protein
analysi
among
sampl
serum
specimen
collect
day
onset
symptom
posit
n
protein
howev
n
protein
detect
beyond
day
group
tabl
group
ii
compris
patient
subsequ
confirm
infect
sarscov
due
posit
serolog
analysi
among
patient
exhibit
seroconvers
pair
two
serum
specimen
acuteand
convalescentphas
serum
specimen
collect
day
day
onset
ill
respect
patient
group
singl
serum
specimen
collect
ill
serolog
analysi
show
igg
posit
sarscov
group
patient
serum
specimen
avail
n
protein
analysi
n
protein
posit
rate
group
collect
day
onset
symptom
respect
tabl
group
iii
compris
patient
whose
convalescentphas
sera
taken
beyond
day
avail
patient
serum
specimen
collect
day
symptom
onset
sampl
collect
day
symptom
onset
sampl
collect
day
symptom
onset
serolog
test
neg
sampl
lack
convalescentphas
serum
obtain
patient
could
judg
mani
patient
truli
infect
sarscov
howev
n
proteinposit
rate
group
sampl
collect
day
onset
fever
respect
tabl
group
iv
compris
patient
pair
serum
specimen
subsequ
exclud
base
convalescentphas
serum
specimen
collect
beyond
day
symptom
onset
neg
sarscov
antibodi
serum
specimen
patient
avail
n
protein
analysi
n
protein
detect
group
tabl
addit
serum
specimen
collect
influenza
patient
specimen
dengu
patient
specimen
measl
patient
serolog
confirm
serum
specimen
healthi
donor
neg
n
protein
detect
specif
tabl
n
protein
captur
elisa
also
use
test
serum
specimen
collect
four
patient
exhibit
sar
recurr
diseas
laboratoryconfirm
sarscov
infect
guangzhou
decemb
januari
shown
tabl
n
protein
detect
serial
serum
specimen
three
patient
taken
within
day
onset
symptom
patient
first
serum
sampl
taken
day
onset
symptom
n
protein
detect
serial
serum
specimen
ill
investig
profil
n
protein
detect
combin
sar
patient
test
posit
neutral
test
sar
patient
serolog
confirm
sarscov
infect
analyz
fig
highest
posit
rate
observ
day
day
onset
symptom
nearli
sera
found
posit
n
protein
day
day
detect
rate
n
protein
decreas
day
never
detect
beyond
day
onset
symptom
previou
studi
demonstr
sarscov
n
protein
could
detect
use
mabbas
antigen
captur
elisa
earli
acut
phase
serum
specimen
patient
sar
studi
confirm
result
use
larg
number
clinic
sampl
well
sampl
obtain
recurr
sar
guangzhou
sinc
sar
new
poorli
understood
diseas
especi
earli
breakout
period
mani
nonsar
patient
may
mislabel
sar
therefor
order
evalu
sensit
specif
assay
accur
data
analysi
base
serolog
diagnosi
use
sampl
patient
serolog
confirm
sarscov
infect
n
protein
sampl
neutral
testposit
patient
sampl
serolog
confirm
patient
taken
day
detect
assay
day
sampl
neutral
testposit
patient
sampl
serolog
confirm
patient
still
posit
n
protein
detect
rate
n
protein
decreas
later
sampl
result
consist
previou
studi
howev
n
protein
could
detect
serum
specimen
taken
day
serum
specimen
taken
day
onset
symptom
patient
exhibit
neg
result
sarscov
antibodi
detect
group
iii
sinc
patient
sar
late
seroconvers
rule
sar
best
test
convalescentphas
serum
collect
beyond
day
onset
symptom
http
although
patient
report
like
infect
sarscov
accord
world
health
organ
criteria
convalescentphas
serum
specimen
collect
beyond
day
avail
patient
know
mani
patient
truli
infect
sarscov
addit
anoth
serum
specimen
ruledout
group
control
serum
specimen
patient
influenza
dengu
measl
healthi
blood
donor
test
n
protein
captur
elisa
posit
result
found
base
serolog
diagnosi
gold
standard
result
demonstr
antigen
captur
elisa
permit
sensit
specif
detect
sarscov
n
protein
clinic
specimen
recent
studi
shown
rtpcr
sarscov
use
nasopharyng
aspir
sampl
appear
best
support
test
earli
diagnosi
howev
variat
report
sensit
specif
make
difficult
rtpcr
consid
standard
criterion
earli
diagnosi
moreov
best
time
high
sensit
nasopharyng
aspir
sampl
day
onset
symptom
later
wait
day
make
firm
diagnosi
plan
appropri
therapi
possibl
sinc
import
diagnos
confirm
sar
within
first
day
ill
studi
n
protein
earli
diagnost
marker
patient
serolog
confirm
sarscov
infect
use
antigen
captur
elisa
abl
demonstr
presenc
n
protein
serum
sampl
earli
day
day
fig
nearli
sera
found
posit
n
protein
day
detect
rate
n
protein
sarscov
serum
specimen
show
much
higher
percentag
blood
first
week
ill
subsequ
week
n
protein
blood
therefor
consid
good
diagnost
marker
earli
stage
sarscov
infect
sinc
n
protein
appear
rel
stabl
freez
thaw
stabl
mani
month
frozen
detect
n
protein
serum
sampl
retrospect
seem
affect
overal
detect
rate
contrast
storag
specimen
essenti
rtpcr
order
maintain
viral
rna
optim
condit
feasibl
mani
nonresearch
laboratori
addit
use
serum
specimen
diagnos
sarscov
infect
advantag
requir
respiratori
specimen
includ
sputum
nasopharyng
aspir
endotrach
tube
sampl
regard
risk
health
care
worker
previou
studi
coronavirus
shown
n
protein
highli
conserv
immunogen
abundantli
express
infect
recent
serolog
studi
use
n
proteinbas
elisa
demonstr
sar
patient
sera
contain
high
level
antibodi
n
protein
immunohistochem
assay
use
mab
specif
n
protein
sarscov
demonstr
n
protein
predominantli
detect
lung
also
mani
organ
tissu
patient
sar
presenc
n
protein
earli
acutephas
sera
patient
sar
find
suggest
n
protein
sarscov
may
major
viral
target
releas
viru
infect
cell
blood
earli
stage
infect
featur
make
n
protein
suitabl
candid
earli
diagnost
applic
n
proteinbas
assay
provid
good
sensit
far
still
clear
whether
sarscov
undergo
high
rate
genet
mutat
although
differ
observ
viral
genom
sequenc
date
correl
viru
load
clinic
outcom
remain
unclear
although
recent
studi
demonstr
clinic
outcom
sar
patient
rtpcrposit
serum
sar
patient
high
viral
load
wors
gener
previou
studi
optic
densiti
n
protein
highli
variabl
one
individu
anoth
day
unclear
data
whether
variat
predict
clinic
outcom
howev
base
clinic
data
avail
abl
find
signific
differ
associ
diseas
sever
level
circul
n
antigen
patient
sar
previou
studi
anim
coronaviru
shown
n
protein
play
import
role
viral
pathogenesi
replic
futur
experi
plan
address
mechan
n
protein
sarscov
present
blood
viral
antigen
role
viral
pathogenesi
andor
replic
conclus
high
sensit
captur
elisa
detect
sarscov
n
protein
serum
sampl
make
use
earli
laboratori
diagnosi
tool
sar
method
overcom
sever
problem
associ
rtpcr
approach
exampl
problem
due
contamin
rtpcr
product
issu
antigen
detect
assay
addit
elisa
rapid
easi
perform
carri
lesswellequip
laboratori
set
wide
employ
assay
enhanc
abil
provid
rapid
respons
event
return
outbreak
sar
